Physician profile
Tracy Johnson
NPI 1568820629
$4,824.99
in general payments reported to CMS, 2019-2025
17 companies · $3,804 in 2025
The $3,804 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $290 · 2023: $167 · 2024: $152 · 2025: $3,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,703 · Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,703.00 |
| Food and Beverage | $420.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,784.75 | 2025 | Austedo Xr |
| Abbvie INC. | $204.18 | 2021-2023 | |
| Glaxosmithkline, LLC. | $129.10 | 2021-2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $119.94 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $118.74 | 2021-2023 | Farxiga |
| Dexcom, INC. | $114.30 | 2024 | Dexcom G7 Gss (161) |
| Novo Nordisk INC | $63.55 | 2021-2022 | |
| Amgen INC. | $50.62 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $39.27 | 2021 | |
| Merck Sharp & Dohme LLC | $38.71 | 2022 | |
| Lilly USA, LLC | $32.42 | 2023 | Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $31.75 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.80 | 2021 | |
| Abbott Laboratories | $18.93 | 2025 | Eterna |
| Pacira Pharmaceuticals Incorporated | $17.31 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $17.01 | 2023 | Firmagon |
| Vanda Pharmaceuticals INC. | $16.61 | 2024 | Hetlioz, Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.